Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
复制标题
DOI：
10.1186/s40425-018-0383-1
复制
发表时间：
2018-07-16
影响因子：
10.9
通讯作者：
Ascierto PA
中科院分区：
文献类型：
--
作者：
Capone M;Giannarelli D;Mallardo D;Madonna G;Festino L;Grimaldi AM;Vanella V;Simeone E;Paone M;Palmieri G;Cavalcanti E;Caracò C;Ascierto PA
以前的研究表明，中性粒细胞/淋巴细胞比率(NLR)的升高预示着各种实体癌症患者预后较差，包括那些接受免疫检查点抑制剂治疗的患者。这是一项对97名连续接受尼伏鲁单抗治疗的IV期黑色素瘤患者的回顾性分析。在单变量和多变量分析中，计算基线NLR和衍生(D)NLR，并与其他特征一起与无进展生存率(PFS)和总生存率(OS)相关。NLR和DNLR的最佳截断值是使用Cutoff Finder软件根据R例程得出的，该程序优化了Kaplan-Meier生存曲线分裂的意义。单因素分析显示，中性粒细胞绝对数(ANC)、NLR、DNLR和乳酸脱氢酶(LDH)(连续变量)升高均与OS显著相关。在多因素分析中，只有NLR(危险比[HR] = 2.85；95%CI 1.60~5.08；p <； 0.0001)和LDH(HR = 2.51；95%CI 1.36~4.64；p <； 0.0001)与OS显著相关。基线≥为5的患者的OS和PFS显著低于NLR和 5的患者，基线为≥3的患者与 3的患者相比也是如此。最佳的分界值为 ≥ 4.7和 ≥ 3.8。使用NLRDN4.7的分界值，OS和PFS的值与值的标准分界值重叠，并且≥<； 3.8也与更好的OS和PFS相关。当基线水平低于临界值时，中性粒细胞/淋巴细胞比率(NLR)和衍生的(D)NLR均与提高存活率有关。NLR和DNLR是简单、廉价和容易获得的生物标志物，可以用来帮助预测晚期黑色素瘤患者对免疫治疗的反应。本文的在线版本(10.1186/s404250180383-1)包含补充材料，授权用户可以使用。
Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio (NLR) is prognostic for worse outcomes in patients with a variety of solid cancers, including those treated with immune checkpoint inhibitors. This was a retrospective analysis of 97 consecutive patients with stage IV melanoma who were treated with nivolumab. Baseline NLR and derived (d) NLR were calculated and, along with other characteristics, correlated with progression-free survival (PFS) and overall survival (OS) in univariate and multivariate analyses. The best cutoff values for NLR and dNLR were derived using Cutoff Finder software based on an R routine which optimized the significance of the split between Kaplan-Meier survival curves. In univariate analysis, increasing absolute neutrophil count (ANC), NLR, dNLR and lactate dehydrogenase (LDH) (continuous variables) were all significantly associated with OS. Only NLR (hazard ratio [HR] = 2.85; 95% CI 1.60–5.08; p < 0.0001) and LDH (HR = 2.51; 95% CI 1.36–4.64; p < 0.0001) maintained a significant association with OS in multivariate analysis. Patients with baseline NLR ≥5 had significantly worse OS and PFS than patients with NLR < 5, as did patients with baseline dNLR ≥3 versus < 3. Optimal cut-off values were ≥ 4.7 for NLR and ≥ 3.8 for dNLR. Using this ≥4.7 cut-off for NLR, the values for OS and PFS were overlapping to the canonical cut-off for values, and dNLR< 3.8 was also associated with better OS and PFS. Both Neutrophil-to-lymphocyte ratio (NLR) and derived (d) NLR were associated with improved survival when baseline levels were lower than cut-off values. NLR and dNLR are simple, inexpensive and readily available biomarkers that could be used to help predict response to immunotherapy in patients with advanced melanoma. The online version of this article (10.1186/s40425-018-0383-1) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
3.4
作者：
Hashimoto, Takeshi;Ohno, Yoshio;Tachibana, Masaaki
通讯作者：
Tachibana, Masaaki
DOI：
10.1038/nrc3239
发表时间：
2012-03-22
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
Pardoll DM
通讯作者：
Pardoll DM
影响因子：
8.8
作者：
Schmidt, H;Bastholt, L;Geertsen, P;Christensen, I;Larsen, S;Gehl, J;von der Maase, H
通讯作者：
von der Maase, H
基线嗜中性粒细胞与淋巴细胞比率与经ipilmimab治疗的转移性黑色素瘤患者的结果有关。
影响因子：
8.8
作者：
Ferrucci PF;Gandini S;Battaglia A;Alfieri S;Di Giacomo AM;Giannarelli D;Cappellini GC;De Galitiis F;Marchetti P;Amato G;Lazzeri A;Pala L;Cocorocchio E;Martinoli C
通讯作者：
Martinoli C
DOI：
10.1056/nejmoa1504030
发表时间：
2015-07-02
期刊：
The New England journal of medicine
影响因子：
--
作者：
Larkin J;Chiarion-Sileni V;Gonzalez R;Grob JJ;Cowey CL;Lao CD;Schadendorf D;Dummer R;Smylie M;Rutkowski P;Ferrucci PF;Hill A;Wagstaff J;Carlino MS;Haanen JB;Maio M;Marquez-Rodas I;McArthur GA;Ascierto PA;Long GV;Callahan MK;Postow MA;Grossmann K;Sznol M;Dreno B;Bastholt L;Yang A;Rollin LM;Horak C;Hodi FS;Wolchok JD
通讯作者：
Wolchok JD